FATE Fate Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FATE

Price (delayed)

$1.28

Market cap

$155.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.03

Enterprise value

$181.06M

?
Relative Growth: Rel. Growth: 8
Relative Strength: Rel. Strength: 27
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 34

Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform ...

Highlights
FATE's EPS is up by 23% year-on-year
The net income has grown by 20% YoY
The company's quick ratio fell by 45% YoY and by 12% QoQ
The company's equity fell by 43% YoY and by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fatetherapeutics.com
Peers: SRPT PTCT BDX NBIX

Key stats

What are the main financial stats of FATE

FATE stock price

How has the Fate Therapeutics stock price performed over time
Intraday
-4.48%
1 week
-30.25%
1 month
-36%
1 year
28.99%
YTD
30.27%
QTD
-45.99%

Financial performance

How have Fate Therapeutics's revenue and profit performed over time
Revenue
$4.75M
Gross profit
$4.75M
Operating income
-$131.1M
Net income
-$124.43M
Gross margin
100%
Net margin
-2,619.6%
The net margin has declined by 35% since the previous quarter and by 20% year-on-year
The operating margin has contracted by 34% from the previous quarter and by 13% YoY
FATE's revenue is down by 33% year-on-year and by 27% since the previous quarter
The gross profit has declined by 33% year-on-year and by 27% since the previous quarter

Price vs fundamentals

How does FATE's price correlate with its fundamentals

Growth

What is Fate Therapeutics's growth rate over time

Valuation

What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
1.15
P/S
33.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
38.12
FATE's EPS is up by 23% year-on-year
FATE's price to book (P/B) is 43% lower than its 5-year quarterly average of 2.0 and 18% lower than its last 4 quarters average of 1.4
The company's equity fell by 43% YoY and by 13% QoQ
FATE's revenue is down by 33% year-on-year and by 27% since the previous quarter
The stock's price to sales (P/S) is 12% less than its last 4 quarters average of 38.0 but 4.5% more than its 5-year quarterly average of 31.9

Efficiency

How efficient is Fate Therapeutics business performance
FATE's return on sales is down by 35% since the previous quarter and by 20% year-on-year
The ROE has contracted by 31% YoY and by 14% from the previous quarter
The ROIC has contracted by 15% YoY and by 9% from the previous quarter
Fate Therapeutics's return on assets has decreased by 12% YoY and by 8% QoQ

Dividends

What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FATE.

Financial health

How did Fate Therapeutics financials performed over time
FATE's total assets is 126% greater than its total liabilities
The company's quick ratio fell by 45% YoY and by 12% QoQ
FATE's current ratio is down by 44% YoY and by 9% from the previous quarter
The debt is 44% smaller than the equity
The company's debt to equity has surged by 65% YoY and by 14% QoQ
The company's equity fell by 43% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.